FOX CHASE CANCER CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1904-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.foxchase.org
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT01462630
- Locations
- 🇺🇸
Hollings Cancer Center Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 340
- Registration Number
- NCT01440855
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
Phase 1
Withdrawn
- Conditions
- Recurrent Salivary Gland CancerRecurrent Verrucous Carcinoma of the Oral CavitySalivary Gland Squamous Cell CarcinomaTongue CancerRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Verrucous Carcinoma of the LarynxRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT01332279
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Phase 2
Completed
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the Larynx
- Interventions
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT01316757
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Univesity of Rochester Medical Center, Rochester, New York, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT01285102
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01281514
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Not Applicable
Terminated
- Conditions
- Interventions
- Drug: fluorouracilDrug: leucovorin calciumDrug: oxaliplatinDrug: irinotecan hydrochlorideDrug: capecitabineGenetic: mutation analysisBiological: bevacizumabBiological: cetuximabGenetic: gene expression analysisOther: laboratory biomarker analysisOther: immunohistochemistry staining methodGenetic: nucleic acid sequencingGenetic: protein expression analysisGenetic: polymerase chain reactionGenetic: DNA analysis
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01280643
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Phase 2
Completed
- Conditions
- Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachStage IA Esophageal CancerStage IA Gastric CancerStage IB Esophageal CancerStage IIB Gastric CancerSquamous Cell Carcinoma of the EsophagusStage IIA Gastric CancerStage IIIA Gastric Cancer
- Interventions
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01212822
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT01183559
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT01169532
- Locations
- 🇺🇸
Fox Chase Cancer Center, Rockledge, Pennsylvania, United States
© Copyright 2024. All Rights Reserved by MedPath